Showing results (21-30 of 505) with videos related to
Sort By:
Pageof 51
Thrombosis and Haemostasis|October 16, 2015
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillationJeffrey I Weitz, John EikelboomCanadian Journal of Surgery. Journal Canadien De Chirurgie|April 15, 2003
Thromboprophylaxis in surgical patientsMartin O'Donnell, Jeffrey I WeitzThrombosis and Haemostasis|June 9, 2017
New developments in anticoagulants: Past, present and futureJeffrey I Weitz, Job HarenbergThe American Journal of Managed Care|May 22, 2004
Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillationMartin O'Donnell, Jeffrey I WeitzAnnals of Internal Medicine|April 6, 2026
In the ED, the Wells score plus age-adjusted D-dimer score ruled out DVT with a failure rate ≤0.8% at 3 moConor Bell, Jeffrey I Weitz, Hematology. American Society of Hematology. Education Program|February 20, 2015
Future prospects for contact factors as therapeutic targetsDavid GailaniThrombosis and Haemostasis|March 23, 2018
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban StudiesAlok A Khorana, Jeffrey I WeitzBritish Journal of Pharmacology|February 16, 2005
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinShannon M Bates, Jeffrey I WeitzAnnals of Internal Medicine|November 1, 2021
In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 moNoel C Chan, Jeffrey I WeitzPageof 51